Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guo, Chuang ^a   Zhang, Shuai ^a   Li, Jia Yi ^a   Ding, Chen ^a   Yang, Zhao Hui ^a   Chai, Rui ^a   Wang, Xu ^b   Wang, Zhan You ^a,c  

^a NORTHEASTERN UNIVERSITY   (China)

^b LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AGER PROTEIN, MOUSE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; HOMEODOMAIN PROTEIN; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; TAU PROTEIN; TRANSACTIVATOR PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; ASTROCYTE; C57BL MOUSE; CELL PROLIFERATION; COGNITIVE DEFECT; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HYPERGLYCEMIA; INFLAMMATION; MAZE TEST; MEMORY DISORDER; METABOLISM; MICROGLIA; MOUSE; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; CELL PROLIFERATION; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GLYCATION END PRODUCTS, ADVANCED; HOMEODOMAIN PROTEINS; HYPERGLYCEMIA; INFLAMMATION; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; OXIDATIVE STRESS; PLAQUE, AMYLOID; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; TAU PROTEINS; TRANS-ACTIVATORS;

EID: 84978409637     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29396     Document Type: Article

References (67)

1. Xu, W. et al. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58, 71-77 (2009).
2. Xu, W., Qiu, C., Winblad, B. & Fratiglioni, L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56, 211-216 (2007).
3. Alafuzoff, I., Aho, L., Helisalmi, S., Mannermaa, A. & Soininen, H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 35, 60-68 (2009).
4. Miklossy, J. et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging 31, 1503-1515 (2010).
5. Valente, T., Gella, A., Fernandez-Busquets, X., Unzeta, M. & Durany, N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. in Neurobiol Dis, Vol. 37, 67-76 (2010).
6. Hardy, J. A. & Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185 (1992).
7. Vassar, R., Kovacs, D. M., Yan, R. & Wong, P. C. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29, 12787-12794 (2009).
8. Kosik, K. S., Joachim, C. L. & Selkoe, D. J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83, 4044-4048 (1986).
9. Sontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S. & Mumby, M. C. Regulation of the phosphorylation state and microtubulebinding activity of Tau by protein phosphatase 2A. Neuron 17, 1201-1207 (1996).
10. Wang, X. et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 5, 46 (2010).
11. Iqbal, K., Liu, F., Gong, C. X., Alonso Adel, C. & Grundke-Iqbal, I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118, 53-69 (2009).
12. Yaffe, K. et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63, 658-663 (2004).
13. Jimenez-Palomares, M. et al. Increased Abeta production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 302, E1373-1380 (2012).
14. Yan, S. D. et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691 (1996).
15. Takeda, S. et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107, 7036-7041 (2010).
16. Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421 (2000).
17. Plaschke, K. et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J Alzheimers Dis 19, 691-704 (2010).
18. Solano, D. C. et al. Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14, 1015-1022 (2000).
19. De Felice, F. G. et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 106, 1971-1976 (2009).
20. Craft, S. et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69, 29-38 (2012).
21. Johnson, J. D. et al. Increased islet apoptosis in Pdx1+ /- mice. J Clin Invest 111, 1147-1160 (2003).
22. Chen, Z. & Zhong, C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108, 21-43 (2013).
23. Arancio, O. et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23, 4096-4105 (2004).
24. Vitek, M. P. et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91, 4766-4770 (1994).
25. Guglielmotto, M. et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 33, 196 e113-127 (2012).
26. Bierhaus, A. & Nawroth, P. P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52, 2251-2263 (2009).
27. Jonsson, J., Carlsson, L., Edlund, T. & Edlund, H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 371, 606-609 (1994).
28. McKinnon, C. M. & Docherty, K. Pancreatic duodenal homeobox-1, PDX-1, a major regulator of beta cell identity and function. Diabetologia 44, 1203-1214 (2001).
29. Brissova, M. et al. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem 277, 11225-11232 (2002).
30. Schwartz, P. T., Perez-Villamil, B., Rivera, A., Moratalla, R. & Vallejo, M. Pancreatic homeodomain transcription factor IDX1/IPF1 expressed in developing brain regulates somatostatin gene transcription in embryonic neural cells. J Biol Chem 275, 19106-19114 (2000).
31. Song, J., Xu, Y., Hu, X., Choi, B. & Tong, Q. Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis 48, 628-634 (2010).
32. Zhao, W., Wu, X., Xie, H., Ke, Y. & Yung, W. H. Permissive role of insulin in the expression of long-term potentiation in the hippocampus of immature rats. Neurosignals 18, 236-245 (2010).
33. Perlmuter, L. C. et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med 77, 1043-1048 (1984).
34. Morris, J. K., Vidoni, E. D., Honea, R. A. & Burns, J. M. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 35, 585-589 (2014).
35. Velayudhan, L. et al. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry 196, 36-40 (2010).
36. Chen, S., Liu, A. R., An, F. M., Yao, W. B. & Gao, X. D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 34, 1211-1224 (2012).
37. Janson, J. et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481 (2004).
38. Carantoni, M. et al. Alzheimer disease and vascular dementia: relationships with fasting glucose and insulin levels. Dement Geriatr Cogn Disord 11, 176-180 (2000).
39. Guo, C. et al. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34, 562-575 (2013).
40. Thambisetty, M. et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 70, 1167-1172 (2013).
41. Farris, W. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100, 4162-4167 (2003).
42. Kim, B., Backus, C., Oh, S., Hayes, J. M. & Feldman, E. L. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150, 5294-5301 (2009).
43. Li, Y. et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19, 1205-1219 (2010).
44. Hiltunen, M. et al. Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J Cell Mol Med 16, 1206-1222 (2012).
45. Jope, R. S. & Johnson, G. V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29, 95-102 (2004).
46. Schechter, R., Beju, D. & Miller, K. E. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 334, 979-986 (2005).
47. Hooper, C. et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 81-86 (2007).
48. Zhao, W. Q. et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 284, 18742-18753 (2009).
49. Bodles, A. M. & Barger, S. W. Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging 26, 9-16 (2005).
50. Jin, Y. et al. Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus. Acta Pharmacol Sin 27, 1309-1316 (2006).
51. de la Monte, S. M. Insulin resistance and Alzheimer's disease. BMB Rep 42, 475-481 (2009).
52. Zhou, X., Feng, Y., Zhan, Z. & Chen, J. Hydrogen sulfide alleviates diabetic nephropathy in a streptozotocin-induced diabetic rat model. J Biol Chem 289, 28827-28834 (2014).
53. Gong, C. X. et al. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65, 732-738 (1995).
54. Liu, R. et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 12, 241-257 (2008).
55. Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I. & Gong, C. X. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582, 359-364 (2008).
56. Simpson, I. A., Chundu, K. R., Davies-Hill, T., Honer, W. G. & Davies, P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 35, 546-551 (1994).
57. Hammes, H. P. et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42, 728-736 (1999).
58. Deane, R. et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913 (2003).
59. Yeh, C. H. et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50, 1495-1504 (2001).
60. Mattson, M. P. Pathways towards and away from Alzheimer's disease. Nature 430, 631-639 (2004).
61. De Felice, F. G. & Ferreira, S. T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 63, 2262-2272 (2014).
62. Bomfim, T. R. et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's diseaseassociated Abeta oligomers. J Clin Invest 122, 1339-1353 (2012).
63. Clarke, J. R. et al. Alzheimer-associated Abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 7, 190-210 (2015).
64. Du Yan, S. et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 94, 5296-5301 (1997).
65. Lue, L. F. et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Experimental neurology 171, 29-45 (2001).
66. Frautschy, S. A. et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152, 307-317 (1998).
67. Macauley, S. L. et al. Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo. J Clin Invest 125, 2463-2467 (2015).